The Filing Desk

Kura Oncology vs Nuvation Bio

Kura Oncology KURA · Nuvation Bio NUVB · Pharmaceuticals

Kura Oncology reported revenue of $68 million in fiscal 2025, about the same as Nuvation Bio's $63 million in fiscal 2025. Kura Oncology's revenue grew 25.2% in its latest year, and Nuvation Bio's grew 699.0%. Kura Oncology had an operating margin of -449.9%, against -338.7% at Nuvation Bio. Free cash flow was −$71 million at Kura Oncology and −$181 million at Nuvation Bio.

Side by side

Kura OncologyNuvation Bio
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$68M$63M
Revenue growth25.2%699.0%
Revenue growth a year, last 5 years——
Gross margin——
Operating margin−449.9%−338.7%
Net margin−412.9%−325.3%
Free cash flow−$71M−$181M
Free cash flow margin−104.8%−288.4%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count1.8%27.1%
Last close$7.77$3.99
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Kura OncologyNuvation Bio
Operating margin
Percent of revenue
Kura OncologyNuvation Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Kura OncologyNuvation Bio

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Kura Oncology and Nuvation Bio pages.